0001453593
false
0001453593
2023-07-10
2023-07-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 10, 2023
XTANT
MEDICAL HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-34951 |
|
20-5313323 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
664
Cruiser Lane
Belgrade,
Montana |
|
59714 |
(Address
of principal executive offices) |
|
(Zip
Code) |
(406)
388-0480
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, par value $0.000001 per share |
|
XTNT |
|
NYSE
American LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 |
|
Entry
into a Material Definitive Agreement. |
As
previously disclosed, on June 18, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into
an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Surgalign Holdings, Inc., a Delaware corporation (the “Seller”),
pursuant to which, subject to the terms and conditions set forth in the Asset Purchase Agreement, the Company agreed to acquire certain
assets of the Seller and its subsidiaries on an as-is, where-is basis, including specified inventory, intellectual property and intellectual
property rights, contracts, equipment and other personal property, records, all outstanding equity securities of the Seller’s international
subsidiaries, and intangibles related to the business of designing, developing and manufacturing hardware medical technology and distributing
biologics medical technology, as conducted by the Seller and its subsidiaries (collectively, the “Assets”), and assume certain
specified liabilities of the Seller and its subsidiaries (collectively, the “Liabilities” and such acquisition of the Assets
and assumption of the Liabilities together, the “Transaction”) for a total purchase price of $5 million in cash.
The
Seller, together with certain of its subsidiaries, is a debtor in a voluntary Chapter 11 case before the United States Bankruptcy Court
for the Southern District of Texas (the “Bankruptcy Court”), which commenced on June 19, 2023. Following Bankruptcy Court
approval, the Company was designated as the “stalking horse” bidder in connection with a sale of the Assets under Section
363 of the Bankruptcy Code. The Transaction will be conducted through a Bankruptcy Court-supervised process pursuant to Bankruptcy Court-approved
bidding procedures and is subject to the receipt of higher or better offers from competing bidders at an auction, approval of the sale
by the Bankruptcy Court, and the satisfaction of certain conditions. The Company can give no assurances of the outcome of the Transaction
and whether the Company will be successful in acquiring the Assets pursuant to the Asset Purchase Agreement.
On
July 10, 2023, the Company and the Seller entered into a First Amendment to Asset Purchase Agreement (the “Amendment”). Pursuant
to the Amendment, the Company and the Seller agreed to extend the date by which the Company may terminate the Asset Purchase Agreement
in the event that the disclosure schedules provided by the Seller are not satisfactory to the Company from 5:00 p.m. Central Time on
July 10, 2023 to 5:00 p.m. Central Time on July 20, 2023. Additionally, the Company and the Seller agreed to amend the Asset Purchase
Agreement to clarify the scope of the mutual releases contained in the Asset Purchase Agreement.
The
foregoing summary of the Amendment is not complete and is qualified in its entirety by reference to the full text of the Amendment, which
is attached hereto as Exhibit 2.1 and is incorporated herein by reference.
Item
9.01 |
|
Financial
Statements and Exhibits. |
(d) Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
XTANT
MEDICAL HOLDINGS, INC. |
|
|
|
|
By:
|
/s/
Sean E. Browne |
|
|
Sean
E. Browne |
|
|
President
and Chief Executive Officer |
|
|
|
Date:
July 11, 2023 |
|
|
Exhibit
2.1
FIRST
AMENDMENT TO
ASSET
PURCHASE AGREEMENT
This
First Amendment to Asset Purchase Agreement (this “Amendment”) is made as of this 10th day of July 2023, by and between
Xtant Medical Holdings, Inc., a Delaware corporation (the “Purchaser”), and Surgalign Holdings, Inc., a Delaware corporation
(“Seller” and together with Purchaser, the “Parties”).
WITNESSETH:
WHEREAS,
Purchaser and Seller entered into that certain Asset Purchase Agreement, dated June 18, 2023 (the “Agreement”) that
provides for, among other things, the purchase by Purchaser of certain assets of Seller and its Subsidiaries predominantly used in or
related to Seller’s and its Subsidiaries hardware and biologics business, and Purchaser assuming from Seller and its Subsidiaries,
certain specified liabilities related thereto, in each case as set forth in the Agreement;
WHEREAS,
clause (B) of Section 7.1(d)(iv) of the Agreement provides that Purchaser may terminate the Agreement by providing to Seller written
notice of termination no later than 5:00 p.m. CT on the date that is five (5) Business Days after receipt by Purchaser of all of the
final Disclosure Schedules if any of the Disclosure Schedules, or any matter, fact, item of information, circumstance, event, Liability
or other disclosure set forth on, or described or referred to in, any of the Disclosure Schedules, shall not be acceptable to Purchaser
in its sole discretion;
WHEREAS,
Purchaser received from Seller final Disclosure Schedules on July 2, 2023 and Purchaser is conducting further diligence with respect
to various matters included on such Disclosure Schedules;
WHEREAS,
Purchaser and Seller wish to amend the Agreement to (i) extend the time by which Purchaser may terminate the Agreement under clause (B)
of Section 7.1(d)(iv) to 5:00 p.m. CT on July 20, 2023 and (ii) clarify certain other provision in the Agreement as provided herein;
and
WHEREAS,
Section 7.12 of the Agreement provides that the Agreement may be amended by the written agreement of Seller and Purchaser.
NOW,
THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and adequacy
of which are hereby acknowledged, the Parties, being all of the parties to the Agreement, hereby agree as follows:
1.
Defined Terms. Capitalized terms used in this Amendment and not otherwise defined shall have the meaning given such terms
in the Agreement.
2.
Amendment to the Agreement. Effective as of the date of this Amendment:
a.
Section 7.1(d)(iv) is amended and restated in its entirety as provided below:
(A)
Seller has not provided complete copies of all of the Disclosure Schedules (other than Schedule 5.7) to Purchaser by 1:00 p.m. CT on
the date that is fourteen (14) days after the date of this Agreement; or (B) if any of the Disclosure Schedules, or any matter, fact,
item of information, circumstance, event, Liability or other disclosure set forth on, or described or referred to in, any of the Disclosure
Schedules, shall not be acceptable to Purchaser in its sole discretion; provided, however, that to terminate this Agreement under this
clause (B), Purchaser must provide to Seller notice of termination no later than 5:00 p.m. CT on July 20, 2023; provided, further, that
Purchaser shall not be permitted to terminate this Agreement pursuant to this Section 7.1(d)(iv) after the date that is the later
of (A) one (1) day prior to the hearing before the Bankruptcy Court seeking entry of the Bid Procedures Order and (B) July 20, 2023.
b.
Section 7.18(b) is hereby amended and restated in its entirety as provided below:
Without
limiting the foregoing, effective as of the Closing Date, Purchaser, on behalf of itself and its respective officers, directors, equityholders,
Subsidiaries (including, as of the Closing, the Acquired Subsidiaries) and Affiliates, and each of their respective successors and assigns
(“Purchaser Releasor”), hereby releases, acquits and forever discharges, to the fullest extent permitted by Law, Seller,
each of other the members of the Parent Group (for the avoidance of doubt, other than any Acquired Subsidiary), and each of their respective
past, present or future officers, managers, directors, equityholders, partners, members, Affiliates, employees, counsel and agents (each,
a “Seller Releasee”) of, from and against any and all Liabilities, actions, causes of action, Claims, demands, damages,
judgments, debts, dues and suits of every kind, nature and description whatsoever, which such Purchaser Releasor or its successors or
assigns ever had, now has or may have on or by reason of any matter, cause or thing whatsoever to the Closing Date, in each case in respect
of any cause, matter or thing relating to the Purchased Assets, the Business or any action taken or failed to be taken by any Seller
Releasee in any capacity related to Seller, the Purchased Assets or the Business occurring or arising on or prior to the Closing Date
(a “Released Claim”), and the Released Claims specifically includes any amounts owed or owing by any of the Seller
Releasees to any Acquired Subsidiary as of the Closing Date. Each Purchaser Releasor agrees not to, and agrees to cause its respective
officers, directors, equityholders, Subsidiaries and Affiliates, and each of their respective successors and assigns not to, assert any
Released Claim against the Seller Releasees. Notwithstanding the foregoing, each Purchaser Releasor and its respective officers, directors,
equityholders, Subsidiaries and Affiliates, and each of their respective successors and assigns retain, and do not release, their rights
and interests under the terms and conditions of this Agreement, the Confidentiality Agreement and the Ancillary Agreements
c.
Section 7.18(c) is hereby amended and restated in its entirety as provided below:
Without
limiting the foregoing, effective as of the Closing Date, Seller, on behalf of itself and its respective officers, directors, equityholders,
Subsidiaries (excluding, for the avoidance of doubt, any Acquired Subsidiaries) and Affiliates, and each of their respective successors
and assigns (“Seller Releasor”), hereby releases, acquits and forever discharges, to the fullest extent permitted
by Law, Purchaser and its past, present or future officers, managers, directors, equityholders, partners, members, Affiliates, employees,
counsel and agents (each, a “Purchaser Releasee”) of, from and against any and all Liabilities, actions, causes of
action, Claims, demands, damages, judgments, debts, dues and suits of every kind, nature and description whatsoever, which such Seller
Releasor or its successors or assigns ever had, now has or may have on or by reason of any matter, cause or thing whatsoever to the Closing
Date, in each case in respect of any cause, matter or thing relating to the Purchased Assets, the Business or any action taken or failed
to be taken by any Purchaser Releasee in any capacity related to Purchaser, the Purchased Assets or the Business occurring or arising
on or prior to the Closing Date (a “Seller Released Claim”), and the Seller Released Claims specifically includes
any amounts owed or owing by any of the Acquired Subsidiaries to any Seller Releasor as of the Closing Date. Each Seller Releasor agrees
not to, and agrees to cause its respective officers, directors, equityholders, Subsidiaries and Affiliates, and each of their respective
successors and assigns not to, assert any Seller Released Claim against the Purchaser Releasees. Notwithstanding the foregoing, each
Seller Releasor and its respective officers, directors, equityholders, Subsidiaries and Affiliates, and each of their respective successors
and assigns retain, and do not release, their rights and interests under the terms and conditions of this Agreement, the Confidentiality
Agreement and the Ancillary Agreements.
3.
No Other Amendments. Except as specifically deemed amended as set forth herein, the Agreement shall remain in full force
and effect in accordance with its terms. The amendments provided in this Amendment shall be applicable solely with respect to those matters
expressly provided herein and no other amendments, waivers or consents may be construed or implied. This Amendment, together with all
documents referenced herein, the other Ancillary Agreements and the Confidentiality Agreement, constitutes the entire agreement between
the Parties, and merges and supersedes all prior and contemporaneous agreements, understandings, negotiations and discussions, both written
and oral, between the Parties with respect to the subject matter hereof and thereof.
4.
Counterparts. This Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to
be an original but all of which taken together shall constitute one and the same agreement.
5.
Miscellaneous. The provisions of Section 7.6 (Governing Law; Jurisdiction; WAIVER OF JURY TRIAL), Section 7.7 other than
the first sentence thereof (Interpretation), Section 7.8 (Notices), Section 7.12 (Amendment), Section 7.14 (Specific Performance), Section
7.15 (Severability), Section 7.16 (Waivers), Section 7.17 (Binding Effect; Third Party Beneficiaries; Assignment), and Section 7.18(a)
(Non-Recourse) of the Agreement shall apply to this Amendment mutatis mutandis.
[SIGNATURE
PAGE FOLLOWS]
IN
WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date first written above.
Seller: |
|
Purchaser: |
|
|
|
Surgalign
Holdings, Inc. |
|
Xtant
Medical Holdings, Inc. |
|
|
|
By: |
/s/
Terry Rich |
|
By: |
/s/
Sean Browne |
Name: |
Terry
Rich |
|
Name: |
Sean
Browne |
Title: |
President,
Chief Executive Officer |
|
Title: |
President
& Chief Executive Officer |
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Xtant Medical (AMEX:XTNT)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Xtant Medical (AMEX:XTNT)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024